Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 19;12(7):1962.
doi: 10.3390/cancers12071962.

Non-Conventional Treatments for Conventional Chondrosarcoma

Varun Monga  1 , Hariharasudan Mani  2 , Angela Hirbe  3 , Mohammed Milhem  1
Affiliations
Review

Non-Conventional Treatments for Conventional Chondrosarcoma

Varun Monga et al. Cancers (Basel). .

Abstract

Chondrosarcomas are the most common malignant tumors of the cartilage, are seen predominantly in adults, and have varied clinical behavior. The majority of them affect the medullary canal of long bones and pelvic bones. The prognosis of chondrosarcoma is closely related to histological grading; however, the grading is subject to interobserver variability. Conventional chondrosarcomas are overall considered to be chemotherapy- and radiation-resistant, resulting in limited treatment options. The majority of advanced conventional chondrosarcomas are treated with chemotherapy without any survival benefit. Recent studies have evaluated molecular genetic findings which have improved the understanding of chondrosarcoma biology. Newer therapeutic targets are desperately needed. In this review article, we explore ongoing clinical trials evaluating novel ways of treating advanced conventional chondrosarcoma.

Keywords: chemotherapy; chondrosarcoma; cyclin-dependent kinase inhibitors; immunotherapy; isocitrate dehydrogenase; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Varun Monga: Research funding and travel expenses from Deciphera. Research funding from Orbus Therapeutics, Immunocellular. Honoraria from Forma Therapeutics; Mohammed Milhem: Research funding from Amgen, Novartis, Merck, Pfizer, ER Squibb & Sons, Prometheus. Honoraria from Blueprint Medicine, Immunocore, Amgen, Trieza. Consulting or advisory role Blueprint Medicine, Amgen, Immunocore, Trieza. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Hariharasudan Mani and Angela Hirbe: The author declares no conflict of interest.

References

    1. Jo V.Y., Fletcher C.D. WHO classification of soft tissue tumours: An update based on the 2013 (4th) edition. Pathology. 2014;46:95–104. doi: 10.1097/PAT.0000000000000050. - DOI - PubMed
    1. Van Praag Veroniek V.M., Rueten-Budde A.J., Ho V., Dijkstra P.D.S., Fiocco M., van de Sande M.A.J. Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas. Surg. Oncol. 2018;27:402–408. doi: 10.1016/j.suronc.2018.05.009. - DOI - PubMed
    1. Mosier S.M., Patel T., Strenge K., Mosier A.D. Chondrosarcoma in childhood: The radiologic and clinical conundrum. J. Radiol. Case Rep. 2012;6:32–42. doi: 10.3941/jrcr.v6i12.1241. - DOI - PMC - PubMed
    1. Wu A.M., Li G., Zheng J.W., Chen C.H., Chen D., Qiao Z.G., Zhao J.G., Wang B., Fu W.L., Sheng S.R., et al. Chondrosarcoma in a paediatric population: A study of 247 cases. J. Child. Orthop. 2019;13:89–99. doi: 10.1302/1863-2548.13.180109. - DOI - PMC - PubMed
    1. Geirnaerdt M.J., Hogendoorn P.C., Bloem J.L., Taminiau A.H., van der Woude H.J. Cartilaginous tumors: Fast contrast-enhanced mr imaging. Radiology. 2000;214:539–546. doi: 10.1148/radiology.214.2.r00fe12539. - DOI - PubMed

LinkOut - more resources